Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow AGIOS PHARMACEUTICALS, INC.

Get SEC filing alerts via email and in your feed for AGIOS PHARMACEUTICALS, INC.

AGIO

AGIOS PHARMACEUTICALS, INC.

About AGIOS PHARMACEUTICALS, INC.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing innovative therapies for rare diseases, particularly in classical hematology. Its lead product, PYRUKYND® (mitapivat), targets hemolytic anemias and is FDA-approved for PK deficiency. With a focus on expanding its portfolio, Agios is advancing treatments for thalassemia and sickle cell disease. The company aims to leverage its expertise in cellular metabolism to address significant unmet medical needs in these areas.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from AGIOS PHARMACEUTICALS, INC.

1
1
AGIOS PHARMACEUTICALS, INC. Agios Pharmaceuticals Reports $20.7M Revenue in Q1 2026, Net Loss Increases to $99.1M

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
AGIOS PHARMACEUTICALS, INC. Agios Pharmaceuticals Reports $54M Revenue Growth and $412.8M Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
AGIOS PHARMACEUTICALS, INC. Agios Pharmaceuticals Reports 43% Revenue Growth but $103.4 Million Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
AGIOS PHARMACEUTICALS, INC. Agios Pharmaceuticals Reports $12.5M Revenue in Q2 2025, Net Loss Increases to $112M

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
AGIOS PHARMACEUTICALS, INC. Agios Pharmaceuticals Reports $89.3 Million Net Loss and $8.7 Million Revenue in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
AGIOS PHARMACEUTICALS, INC. Agios Pharmaceuticals Reports $673.7M Net Income Turnaround, Expands Product Pipeline

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
AGIOS PHARMACEUTICALS, INC. Agios Pharmaceuticals Reports Significant Financial Turnaround, Net Income Surges to $947.9 Million in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments